Once we discovered that the overexpression of UbcH10 was inversely correlated with the presence of EGFR mutations in NSCLC specimens [17], we asked whether UbcH10 expression could be involved in the modulation of sensitivity to therapy. Here, UBE2C is linked to non-small cell lung carcinoma.